Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.
Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 3, 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Disc Medicine Inc
Entrinsic Bioscience Inc
Iron4u Aps
Jiangsu Aosaikang Pharmaceutical Co Ltd
Keros Therapeutics Inc
Nemysis Ltd
Novartis AG
Pharmacosmos AS
Renibus Therapeutics Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Vifor Pharma Ltd
Iron Deficiency Anemia - Drug Profiles
AKB-5343 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DISC-0974 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ferric bepectate - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
ferric derisomaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
History of Events
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
IHAT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
iron sucrose - Drug Profile
Product Description
Mechanism Of Action
History of Events
KER-047 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KTI-016 - Drug Profile
Product Description
Mechanism Of Action
KTI-018 - Drug Profile
Product Description
Mechanism Of Action
KTI-2338 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody 1 to Inhibit Hemojuvelin for Chronic Inflammation and Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
PT-30 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-007 - Drug Profile
Product Description
Mechanism Of Action
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Discontinued Products
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Feb 04, 2022: Shield Therapeutics: Innovation in iron deficiency treatment with a focus on clinical utility of Accrufer/Feraccru
Dec 20, 2021: Vifor Pharma and American Regent announce settlement of Injectafer patent litigation
Dec 16, 2021: Shield Therapeutics: Patient access expands for Accrufer
Dec 16, 2021: Injectafer (ferric carboxymaltose injection) receives FDA approval for the treatment of pediatric patients with iron deficiency anemia
Dec 14, 2021: Rockwell Medical receives important feedback from FDA on its IND application for phase 2 trial of ferric pyrophosphate citrate in home infusion
Nov 16, 2021: Rockwell Medical study demonstrates no drug-drug interaction between ferric pyrophosphate citrate and unfractionated heparin
Nov 11, 2021: Rockwell Medical submits investigational new drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion
Nov 04, 2021: Rockwell Medical presents Triferic real world evidence update at ASN Kidney Week 2021
Aug 31, 2021: Vifor Pharma’s Ferinject granted new recommendations in updated 2021 ESC heart failure guidelines
Aug 09, 2021: Shield Therapeutics: AEGIS-CKD study results published in AJKD
Jun 28, 2021: Rockwell Medical files pre-IND meeting request with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion
Jun 24, 2021: Shield Therapeutics: US launch of Accrufer confirmed for July 1, 2021
May 21, 2021: Shield Therapeutics: US update
May 18, 2021: Shield Therapeutics: AEGIS-H2H study results published in Inflammatory Bowel Diseases
May 12, 2021: Nemysis announces grant of first Chinese patent for IHAT
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Iron Deficiency Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Disc Medicine Inc, 2022
Iron Deficiency Anemia - Pipeline by Entrinsic Bioscience Inc, 2022
Iron Deficiency Anemia - Pipeline by Iron4u Aps, 2022
Iron Deficiency Anemia - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
Iron Deficiency Anemia - Pipeline by Keros Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Nemysis Ltd, 2022
Iron Deficiency Anemia - Pipeline by Novartis AG, 2022
Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, 2022
Iron Deficiency Anemia - Pipeline by Renibus Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, 2022
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, 2022
Iron Deficiency Anemia - Pipeline by Vifor Pharma Ltd, 2022
Iron Deficiency Anemia - Dormant Projects, 2022
Iron Deficiency Anemia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Iron Deficiency Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
